An analysis compares Pfizer Inc. (PFE) and BioNTech SE (BNTX) to determine which pharmaceutical giant is better positioned for the market and healthcare landscape in the post-COVID era.

BMO Capital has reduced its price target for BioNTech SE (BNTX) from $143 to $128.

BioNTech SE (BNTX) is experiencing a rally in its stock due to a solid oncology strategy.

An article evaluates whether BioNTech SE (BNTX) is a good stock investment opportunity at the current time.

The founding couple of Biontech is stepping down from operational roles, prompting the company to search for a new CEO, primarily in the United States. The largest shareholder defends the move, while Mainz hopes not to lose a valuable asset.

Morgan Stanley has slightly raised its price target for BioNTech SE (BNTX) as it updates its biopharma coverage models.